Are Semaglutides Safe?

"Is semaglutide safe?" has no yes-or-no answer, and anyone who gives you one is selling something. Semaglutide's safety is documented in detail in its FDA labeling — including a boxed warning — and it is conditional on who is taking it. FDA labeling for semaglutide reports that adverse reactions to semaglutide were evaluated in 3 randomized, double-blind, placebo-controlled trials that included 2,116 adults treated with 2.4 mg semaglutide injection for up to 68 weeks for weight reduction. That is a real evidence base, and it is also why semaglutide is prescription-only: the answerable question isn't "is semaglutide safe?" in general, it's whether it is appropriate for you — and only a medical provider licensed in your state who has reviewed your health history can answer that.

Here is what the labeling and the trials actually say, including the parts worth taking seriously.

What semaglutide is

The clinical pharmacology section of FDA labeling for semaglutide for weight reduction describes semaglutide as a GLP-1 analogue with 94% sequence homology to human GLP-1 that selectively binds to and activates the GLP-1 receptor. The clinical pharmacology section of FDA labeling for semaglutide also states that GLP-1 is a physiological regulator of appetite and caloric intake, and that the GLP-1 receptor is present in several areas of the brain involved in appetite regulation, and that animal studies show semaglutide distributed to and activated neurons in brain regions involved in regulation of food intake.

The same molecule is sold under different brand names with different approved uses. Wegovy® (semaglutide) is FDA-approved to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced calorie diet and increased physical activity. Ozempic® (semaglutide) is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

What the clinical trials showed

In the STEP 1 trial, 1961 adults with overweight or obesity were randomly assigned to 68 weeks of once-weekly subcutaneous semaglutide 2.4 mg or placebo, plus lifestyle intervention. On the safety side:

• In the STEP 1 trial, nausea and diarrhea were the most common adverse events with semaglutide, and they were typically transient and mild-to-moderate in severity and subsided with time.
• In the STEP 1 trial, 4.5% of participants who received semaglutide discontinued treatment owing to gastrointestinal events, compared with 0.8% of participants who received placebo.
• FDA labeling for semaglutide reports that 6.8% of adults treated with 2.4 mg semaglutide injection for weight reduction permanently discontinued treatment as a result of adverse reactions to semaglutide, compared with 3.2% of adults treated with placebo.

Those results describe the brand-name products studied in the trials, and individual experiences vary.

Common side effects: what to expect

FDA labeling for semaglutide lists nausea, diarrhea, vomiting, constipation, abdominal pain, headache, and fatigue among reported adverse reactions to semaglutide in adults treated for weight reduction. Each figure below is that labeling's reported rate in adults treated with 2.4 mg semaglutide injection, compared with placebo:

• Nausea. FDA labeling for semaglutide lists nausea among reported adverse reactions to semaglutide, in 44% of semaglutide injection-treated adults treated for weight reduction, compared with 16% of placebo-treated adults.
• Diarrhea. FDA labeling for semaglutide lists diarrhea among reported adverse reactions to semaglutide, in 30% of semaglutide injection-treated adults treated for weight reduction, compared with 16% of placebo-treated adults.
• Vomiting. FDA labeling for semaglutide lists vomiting among reported adverse reactions to semaglutide, in 24% of semaglutide injection-treated adults treated for weight reduction, compared with 6% of placebo-treated adults.
• Constipation. FDA labeling for semaglutide lists constipation among reported adverse reactions to semaglutide, in 24% of semaglutide injection-treated adults treated for weight reduction, compared with 11% of placebo-treated adults.
• Headache and fatigue. FDA labeling for semaglutide lists headache among reported adverse reactions to semaglutide, in 14% of semaglutide injection-treated adults treated for weight reduction, compared with 10% of placebo-treated adults. FDA labeling for semaglutide lists fatigue among reported adverse reactions to semaglutide, in 11% of semaglutide injection-treated adults treated for weight reduction, compared with 5% of placebo-treated adults.

Practical habits help: smaller meals eaten slowly, gentler foods in the early weeks, steady hydration, and a consistent injection day. If your provider prescribes it, anti-nausea medication (ondansetron) is included in every Ladies First plan at no extra charge.

The rare-but-serious risks

FDA labeling for semaglutide lists acute pancreatitis, acute gallbladder disease, hypoglycemia, acute kidney injury, severe gastrointestinal adverse reactions, and hypersensitivity reactions among the serious adverse reactions to semaglutide. Being honest about safety means naming them plainly, in the labeling's own terms:

• Pancreatitis. FDA labeling for semaglutide states that acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including semaglutide for weight reduction. FDA labeling for semaglutide directs that patients treated with semaglutide for weight reduction be observed for signs and symptoms of acute pancreatitis, which may include persistent or severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting, and directs that semaglutide be discontinued if pancreatitis is suspected.
• Gallbladder disease. FDA labeling for semaglutide reports cholelithiasis in 1.6% of semaglutide injection-treated adults treated for weight reduction, compared with 0.7% of placebo injection-treated adults. FDA labeling for semaglutide also states that substantial or rapid weight loss can increase the risk of cholelithiasis, and reports that acute gallbladder disease was more frequent in semaglutide-treated patients than in placebo-treated patients. Watch for pain in the upper right abdomen, especially after fatty meals.
• Thyroid C-cell tumors. FDA labeling for semaglutide carries a boxed warning for risk of thyroid C-cell tumors from semaglutide. The boxed warning in FDA labeling for semaglutide states that in rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. The boxed warning in FDA labeling for semaglutide further states that it is unknown whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
• Severe gastrointestinal reactions. FDA labeling for semaglutide lists severe gastrointestinal adverse reactions to semaglutide and states that semaglutide for weight reduction is not recommended in patients with severe gastroparesis.

Interactions worth flagging

FDA labeling for semaglutide states that semaglutide for weight reduction delays gastric emptying and may impact the absorption of concomitantly administered oral medications. FDA labeling for semaglutide also states that in clinical pharmacology trials with semaglutide 1 mg once weekly injection, semaglutide did not affect the absorption of orally administered medications — so this is a monitoring point, not a blanket alarm. FDA labeling for semaglutide further states that the risk of hypoglycemia is increased when semaglutide for weight reduction is used concomitantly with insulin or insulin secretagogues such as sulfonylureas. Bring your full medication list to your provider — that is exactly what it is for.

Who shouldn't take semaglutide

The labeling is specific about this, and so is a good provider:

• FDA labeling for semaglutide lists a personal or family history of medullary thyroid carcinoma (MTC), and Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), among the contraindications to semaglutide for weight reduction.
• FDA labeling for semaglutide lists a prior serious hypersensitivity reaction to semaglutide, or to any of the excipients in the semaglutide product, among the contraindications to semaglutide for weight reduction.

Pregnancy is handled differently from a contraindication, and the distinction matters. FDA labeling for semaglutide directs that semaglutide be discontinued in pregnant patients who are using semaglutide for weight reduction, and states that weight loss offers no benefit to a pregnant patient and may cause fetal harm. If you are pregnant, planning a pregnancy, or breastfeeding, that is a conversation to have with your provider before you start, not after.

Other histories — pancreatitis, gallbladder disease, significant kidney disease, diabetic retinopathy, gastroparesis, eating disorders — don't always mean "no," but they require a provider's careful judgment and sometimes extra monitoring.

One more distinction that matters: brand-name vs. compounded

Everything above describes the FDA labeling and the clinical trials for the brand-name products — Wegovy® and Ozempic®. The adverse-reaction rates quoted on this page come from trials of Wegovy® itself. Compounded medications are not FDA-approved. They are prepared in FDA-regulated facilities. If you're weighing that option, read our honest breakdown in Are Compounded Semaglutides Safe? — and know that whether any version is appropriate for you is your provider's call, not a checkout option.

How safety is handled in real care

Safety isn't a one-time screening — it's built into how treatment runs. FDA labeling for semaglutide directs that semaglutide injection for weight reduction be initiated at a dosage of 0.25 mg once weekly for 4 weeks and then escalated, titrating every 4 weeks, to the usual recommended maintenance dosage of 2.4 mg once weekly, which is why nobody starts at the top dose. Your provider adjusts based on how you respond, follow-ups and messaging support are included, and lab work is ordered when your provider needs it. If anything feels wrong between visits, you message your care team — you're never managing this alone.

The bottom line

Semaglutide has a well-characterized safety profile, and "well-characterized" is not the same as "safe for everyone." The labeling documents mostly gastrointestinal side effects at meaningful rates, a small number of serious risks, a boxed warning, and two hard contraindications. Whether that profile fits your body and history is a medical decision — made by a medical provider licensed in your state, not by a blog post, and never by marketing.

Find out what's appropriate for you. Answer a few health questions online — it takes about 3 minutes, costs nothing, and a medical provider licensed in your state reviews everything, usually within 48 hours. You're never charged unless a provider approves your plan.

Sources

1. FDA labeling (DailyMed) — WEGOVY (semaglutide) injection and tablets: Boxed Warning (Risk of Thyroid C-Cell Tumors); Indications and Usage; Contraindications; Warnings and Precautions (Acute Pancreatitis; Acute Gallbladder Disease; Hypoglycemia; Severe Gastrointestinal Adverse Reactions); Adverse Reactions; Drug Interactions; Use in Specific Populations (Pregnancy); Dosage and Administration; Clinical Pharmacology (Mechanism of Action). Novo Nordisk.
2. FDA labeling (DailyMed) — OZEMPIC (semaglutide) injection: Indications and Usage; Boxed Warning (Risk of Thyroid C-Cell Tumors). Novo Nordisk.
3. Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID 33567185.

Standing §1.4 disclosure block renders as the bottom fine-print band on this page (see HUB-DRAFT.md §6).